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ABSTRACT
Introduction Paediatric transplantation is the only 
curative therapeutic procedure for several end- stage 
rare diseases affecting different organs and body 
systems, causing altogether great impact in European 
children’s health and quality of life. Transplanted 
children shift their primary disease to a chronic 
condition of immunosuppression to avoid rejection. 
Longer life expectancy in children poses a greater risk 
of prolonged and severe side effects related to long- 
term immunosuppressive (IS) disabilities and secondary 
cancer susceptibility. The goal remains to find the best 
combination of IS agents that optimises allograft survival 
by preventing acute rejection while limiting drug toxicities. 
This systematic review will aim to determine the optimal IS 
strategy within the so- called minimisation, conversion or 
withdrawal strategies.
Methods and analysis We will search the following 
databases with no language restrictions: Cochrane Central 
Register of Controlled Trials in the Cochrane Library, 
OvidSP Medline and Epub Ahead of Print, In- Process & 
Other Non- Indexed Citations and Daily; OvidSP Embase 
Classic+Embase; Ebsco CINAHL Plus, complete database; 
WHO International Clinical Trials Registry Platform search 
portal. We will include controlled and uncontrolled clinical 
trials along with any prospective or retrospective study 
that includes a universal cohort (all participants from a 
centre/region/city over a certain period). Cases series 
and cross- sectional studies are excluded. Two review 
authors will independently assess the trial eligibility, risk 
of bias and extract appropriate data points. The outcomes 
included in this review are: patient survival, acute graft 
rejection, chronic graft rejection, diabetes, graft function, 
graft loss, chronic graft versus host disease, acute graft 
versus host disease, surgical complications, infusion 
complications, post- transplant lymphoproliferative disease, 
liver function, renal function, cognition, depression, health- 
related quality of life, hospitalisation, high blood pressure, 
low blood pressure, cancer—other, cancer—skin, 
cardiovascular disease, bacterial infection, Epstein- Barr 




The treatment of choice for end- stage solid- 
organ failure in children in most cases is solid 
organ transplantation (SOT) or haematopoi-
etic stem cell transplantation (HSCT) for the 
treatment of haematological malignancies, 
immune- deficiency illnesses or inherited 
metabolic disorders or haemoglobinopa-
thies. Both SOT and HSCT offer the chance 
of a cure, but at the same time raise the risk 
of treatment- related mortality and long- term 
side effects.
Between 2012 and 2016, 7741 solid organ 
transplants were performed on children in 23 
European Union (EU)1 countries and 4041 
paediatric patients received HSCT.2 3 The 
clinical consequences of transplantation can 
be understood as those (i) directly related to 
Strengths and limitations of this study
 ► The search strategies and lack of dates and lan-
guage restriction will provide an exhaustive review 
of the topic.
 ► The review will cover all types of study designs aim-
ing to capture all relevant information.
 ► A large number of studies with high risk of bias are 
expected and they will be clearly analysed.
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the transplanted organ (acute or chronic allograft rejec-
tion, native disease within the allograft, surgical complica-
tions), (ii) arising primarily from post- transplant therapies 
(infection, malignancy, pharmacological toxicity, growth 
retardation), (iii) linked to the underlying disease (recur-
rence of original disease in some allografts) and (iv) 
being multifactorial.
Despite the rate of graft success has improved along 
with the patient’s clinical outcomes by development and 
improvements of surgical techniques, anaesthetic proce-
dures and post- transplant care, especially immunosup-
pression, the patients still need immunosuppressive (IS) 
agents to prevent rejection of the transplanted organ to a 
greater or lesser extent whether SOT or HSCT. Therefore, 
transplanted children have shifted to a chronic condition 
dependent on IS treatment to avoid grafted organ rejec-
tion or graft versus host disease. Consequences of post- 
transplant IS in children fall into two broad categories: 
direct organ toxicity and non- specific IS action (ie, infec-
tion and malignancy). This chronic condition requires 
proper monitoring and care of post- transplant compli-
cations such as infections, malignancy and chronic rejec-
tion, which is even more important in children as they 
have higher pretransplantation and post- transplantation 
mortality and morbidity rates than adults.
Challenges in paediatric transplantation
IS management is challenging in infants, children and 
young people. It requires tailored post- transplant manage-
ment to the unique needs of the youngster. Physiolog-
ical immaturity of many systems including the immune 
system, growing and development and other consider-
ations make paediatric transplantation a singular entity 
when compared with adult transplantation. Diagnostic 
and therapeutic advances achieved in adult transplant are 
not necessarily applicable to paediatric transplantation 
and require a distinct pipeline of development. Special-
ised clinical and laboratory resources that support the 
transplantation procedure in common processes such as 
immunosuppression, immune reconstitution, rejection, 
tolerance, risk of infection and secondary malignancies 
are needed in order to accelerate research and new ther-
apies. In addition, other areas of non- medical supportive 
care are demanded for children and their families, due 
to severe psychological and socioeconomic issues that 
extend to adulthood. A paediatric disease affects the 
whole family, as impairments of a child’s function are a 
source of emotional distress for parents. Parents of trans-
planted children have been found to show post- traumatic 
stress disorder, feeling particularly distressed during the 
post- transplantation phase.4 These problems may affect 
the child’s daily- life function and include a broad spec-
trum of somatic, psychological and social problems.
Furthermore, despite improvements in short- term graft 
survival, the immunosuppressive regimens have failed to 
prolong long- term graft survival, being estimated between 
5 and 20 years for SOT and 1–2 years for HSCT.5 The 
paediatric transplantation demands even more expertise 
in reference centres connecting multidisciplinary medical 
expertise, transfer of knowledge and innovative medicine.
Minimisation, conversion or withdrawal strategies in 
paediatric transplantation recipients
The optimal immunosuppressive regimen maintains 
graft function (GF), minimising rejection and graft 
versus host disease while limiting the potential for infec-
tion and organ toxicity. The IS treatment for SOT have 
not changed during the last years. It remains calcineurin 
inhibitors (CNI) mostly in association with steroids in the 
short- term and mycophenolate mofetil or mammalian 
target of rapamycin inhibitors (everolimus, sirolimus) in 
the mid- term or long term. As mentioned, CNI such as 
tacrolimus have improved short- term but not long- term 
graft survival. Prolonged use of IS drugs leads to neph-
rotoxicity, metabolic disorders, infections and cancer. 
Biomarkers of tolerance will help us to stratify patients at 
different stages, tailor and individualise treatment, consid-
ering the special characteristics of paediatric patients. In 
HSCT, IS is withdrawn in most of the patients 1–2 years 
post- transplantation. Furthermore, limited availability 
of fully match human leucocyte antigen donors has 
developed strategies of graft engineering to overcome 
mismatch related and unrelated donors. In this setting, 
total T cell depletion, as CD34+ selection, CD3CD19 
depletion or partial T cell depletion as αβ T- cell/CD19 
B- cell depletion and CD45RA+ depletion, have shown 
promising clinical results in paediatric patients. The most 
important issue is that this kind of graft engineering allows 
the absence of post- HSCT pharmacological prophylaxis 
early after HSCT.6 7
Strategies to limit the impact of prolonged IS include 
protocols of drug minimisation towards individualisation 
of organ- specific immunosuppression regimens, develop-
ment of new non- nephrotoxic agents and trials of toler-
ance induction. The lack of consensual and standardised 
post- transplant care in paediatric patients is also a limita-
tion for the design of clinical trials and for drawing 
conclusions that can be used in the clinical settings. The 
small number of SOT and HSCT performed in paediatric 
patients per year remains a challenge for research in this 
field, which is even more evident when the analysis is 
focused on certain organs such as heart and lungs. Some 
of the limitations of paediatric transplantation are asso-
ciated with the inability to translate the results obtained 
from adult studies to paediatric studies examining similar 
diseases and procedures.
European reference networks
The EU, through the 2009 recommendation, advised on 
the identification of centres of expertise in rare diseases 
in order to overcome some of the challenges that they 
face: scarcity of patients, resources and expertise. The 
multidisciplinary approach of the centres of expertise will 
improve patient diagnosis, treatments and quality of life 
(QoL). In March 2017, the EU8 launched 24 European 
Reference Networks (ERNs), which are virtual networks 
 on M









pen: first published as 10.1136/bm






3Martin Saborido C, et al. BMJ Open 2020;10:e037721. doi:10.1136/bmjopen-2020-037721
Open access
involving healthcare providers across Europe. ERNs were 
created to tackle rare diseases and complex conditions 
requiring highly specialised healthcare by gathering 
knowledge and expertise that will result in better patient 
care.
ERN TransplantChild is one of the 24 ERNs estab-
lished in a European legal framework.9 ERN Transplan-
tChild is the only ERN focused on a complex and highly 
specialised process, the paediatric transplantation of both 
SOT and HSCT with a process approach rather than an 
organ approach. Eighteen healthcare providers from 11 
Member States of the EU integrate ERN TransplantChild. 
The reasoning behind is that paediatric transplantation 
requires highly specialised centres with highly dedicated 
and multidisciplinary teams with different transplanta-
tion programmes and teams involved including common 
aspects to all transplants and favouring the implementa-
tion of new diagnostic tools and treatments. The network 
addresses the entire transplant process: pretransplant, 
transplant and post- transplant phases, dealing with a new 
chronic condition and preventing secondary transplant- 
associated diseases. ERN TransplantChild aims at the 
empowerment and the improvement of life expectancy 
and QoL for EU paediatric patients requiring a SOT or 
HSCT or transplanted patients and patients’ families.
In this framework, ERN TransplantChild executive 
committee decided to develop a clinical practice guide-
line on the effects of the minimisation, conversion or 
withdrawal immunosuppression strategies in paediatric 
SOT and HSCT. To address this issue, the ERN defined 
the question to be answered through a systematic review. 
In the present article, we describe the protocol of this 
particular systematic review registered in PROSPERO 
with ID: CRD42019136524.
OBJECTIVE
To determine the effects of the minimisation, conversion 
or withdrawal immunosuppression strategies in paediatric 
solid organ and haematopoietic stem cell transplantation.
METHODS AND ANALYSIS
This systematic review started in April 2020 and was 
intended to be finished by July 2020.
Criteria for considering studies for this review
Type of studies
This review will consider controlled and uncontrolled 
clinical trials along with any prospective or retrospective 
study that includes a universal cohort (all participants 
from a centre/region/city over a certain period). Cases 
series and cross- sectional studies are excluded.
Type of participants
The systematic review will include studies on paediatric 
population (0–18 years) in any stage of the transplanta-
tion process: pretransplantation or post- transplantation.
Type of interventions
Any immunosuppression strategy at any stage of the 
transplantation process, that is, any IS medication used 
such as steroids, calcineurin inhibitors, mycophenolic 
acid, sirolimus, everolimus… prescribed to the patients 
on different regimens or strategies as withdrawal, mini-
misation or conversion. Biological treatments should be 
excluded as these are out of the review’s scope. Evalua-
tion of conditioning regimens only should be excluded
The comparators could be any intervention defined 
previously or any control. We included, as well, no 
controlled trials so in this case no comparator could be 
possible. The uncontrolled cohorts will be used by the 
CPG panel of experts as complementary information, 
but the data extracted from those uncontrolled cohorts 
will not be summarised nor included in the summary of 
finding tables.
Type of outcome measures
Primary outcomes
 ► Patient survival: proportion of subjects who are alive 
after transplantation at any timepoint.
 ► Acute graft rejection: clinically diagnosed or through 
biopsy of histological samples so they are not solely 
based on time of occurrence, are based on the defini-
tion from investigators in each of the studies or based 
on histological samples or clinical diagnose. We will 
use T- cell- mediated rejection and antibody- mediated 
rejection, rather than acute and chronic, according to 
the new Banff classification whenever will be possible. 
At at least within 6 months from transplantation.
 ► Chronic graft rejection: clinically diagnosed or 
through biopsy of histological samples so they are not 
solely based on time of occurrence, are based on the 
definition from investigators in each of the studies or 
based on histological samples or clinical diagnose. 
We will use T- cell- mediated rejection and antibody- 
mediated rejection, rather than acute and chronic, 
according to the new Banff classification whenever 
will be possible. At at least within 6 months from 
transplantation.
 ► Diabetes measured based on A1C criteria or plasma 
glucose criteria, either the fasting plasma glucose 
or the 2- hour plasma glucose value after a 75 g oral 
glucose tolerance test at any time.
 ► GF:
 – GF kidney: glomerular filtrate rate at any timepoint.
 – GF liver: at least liver transaminases+bilirubin at any 
timepoint+prothrombin time (PT)+international 
normalised ratio (INR)+serum lactate+ammonia 
levels.
 – GF lung: forced expiratory volume in 1 s+forced vi-
tal capacity at any timepoint.
 – GF heart: at least ejection fraction at any timepoint 
and graft vasculopathy.
 – GF intestine: at least citrulline+absorption faecal 
test at any timepoint.
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 – GF HSCT: count of leucocytes+platelet+haemoglo-
bin+lymphocytes at any timepoint.
 ► Graft loss: defined as any medical or surgical condi-
tion requiring re- transplantation, such as primary 
graft dysfunction or non- function and death at any 
timepoint.
 ► Acute graft versus host disease: biopsy of histological 
sample at any timepoint.
 ► Chronic graft vs host disease: biopsy of histological 
sample at any timepoint.
 ► Surgical complications: any complication identified 
by the investigators.
 ► Infusion complications: any complication identified 
by the investigators during the infusion process for 
stem cell transplantation.
 ► Post- transplant lymphoproliferative disease (PTLD): 
biopsy of histological sample at any timepoint.
 ► Liver function: liver transaminases+bilirubin at any 
timepoint+PT+INR+serum lactate+ammonia levels.
 ► Renal function: glomerular filtration rate at any 
timepoint.
 ► Cognition measured by the IQ at any timepoint.
 ► Depression change in depression score from baseline 
to 6 or 12 months.
 ► Health- related quality of life (HRQoL): measured 
using any validated HRQoL scale for children or 
caregivers.
 ► Hospitalisation: number of hospitalisations from 
transplantation at any time point.
 ► High blood pressure: defined by investigators at any 
timepoint.
 ► Low blood pressure: defined by investigators at any 
timepoint.
 ► Cancer—other (not skin not PTLD): any cancer iden-
tified by investigators at any timepoint.
 ► Cancer—skin: any skin cancer identified by investiga-
tors at any timepoint.
 ► Cardiovascular disease: any cardiovascular disease 
identified by investigators at any timepoint.
 ► Bacterial infection: positive culture.
 ► Epstein- Barr infection: at least two positive determi-
nations of EBV DNA- emia by PCR in blood test and 
confirmed histologically without evidence of EBV- 
PTLD. EBV- PTLD should be based on at least two of 
the following histological features defined by WHO10: 
(i) disruption of underlying cellular architecture by 
a lymphoproliferative process, (ii) presence of mono-
clonal or oligoclonal cell populations as revealed by 
cellular and/or viral markers, (iii) evidence of EBV 
infection in many of the cells, that is, DNA, RNA or 
protein. Detection of EBV nucleic acid in blood is not, 
eo ipso, sufficient for the diagnosis of EBV- PTLD.
 ► Cytomegalovirus infection/disease: PCR in blood test 
and confirmed histologically.
 ► Other viral infections: identified by investigators using 
PCR, histology, culture or serology.
 ► Growth: measured using at least height and weight 
from transplantation to any timepoint.
Secondary outcomes
 ► Age at transplantation.
 ► Age of participants at any analysis of primary outcomes 
provided by the authors of included studies.
Search methods for identification of studies
We will search for all published studies and will review 
the list of references as well of included studies to find 
potential relevant studies. All searches will be done from 
inception until end of March 2019.
Electronic searches
In accordance with the Cochrane handbook, we launched 
search strategies search for the following electronic 
databases:
1. Cochrane Central Register of Controlled Trials 
(CENTRAL; 2019, Issue 3) in the Cochrane Library.
2. OvidSP Medline and Epub Ahead of Print, In- Process 
& Other Non- Indexed Citations and Daily.
3. OvidSP Embase Classic+Embase.
4. Ebsco CINAHL Plus, complete database.
5. Trial registers:
1. WHO International Clinical Trials Registry Platform 
search portal.11
Search strategy for Medline is in online supplemental 
Annex I.
Data collection and analysis
Selection of studies
At least two authors from the following list will inde-
pendently screen titles and abstracts and assess full- text 
articles from potentially eligible studies:
Dr Carlos Martín Saborido. IdiPAZ
Dr Antonio Carcas Sansuán. Hospital Universitario La 
Paz
Dr Juan Torres. IdipAZ
Dr Alistair Baker. King’s College London KCH Trust
Dr Caroline Lindemans. Wilhelmina Children’s 
Hospital
Dr Daniela Liccardo. Ospedale Pediátrico Bambino 
Gesú
Dr Emanuele Nicastro. Ospedale Papa Giovani XXIII
Dr Elisa Benetti. Azienda Ospedaliera di Padova
Dr Lucía Martínez. Hospital Universitario La Paz
Dr Jaime Montserrat Villatoro. Hospital Universitario 
La paz
Dr Elena Sánchez Zapardiel. Hospital Universitario La 
Paz
Dr Luz Yadira Bravo. Hospital Universitario La Paz
Dr María Francelina Lopes. Centro Hospitalar e Univer-
sitario de Coimbra
Dr Carmen Capito. Hôpital Necker- Enfants Malades
Dr Alastair Baker. Kings College London KCH Trust
Dr Dominique Debray. Hôpital Necker- Enfants Malades
Dr Jacek Toporski. Children’s Hospital, Skåne Univer-
sity Hospital
Dr Esther Ramos. Hospital Universitario La Paz
Dr Florance Lacaille. Hôpital Necker- Enfant Malades
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Dr Imeke Goldschmidt. Hannover Medical School
Dr Lars Pape. Hannover Medical School
Dr Ulrich Baumann. Hannover Medical School
If there is no consensus between both authors involved 
in the screening or assessment, a third one, Carlos Martín 
Saborido (CMS) will intervene to solve the disagreement. 
We will use COVIDENCE as a screening and extraction 
tool to implement the selection process.12 We will docu-
ment the reasons for the exclusion of the full- text articles 
we assessed.
We will construct a flow chart to illustrate selection of 
studies included in this review according to Preferred 
Reporting Items for Systematic Reviews and Meta- Analyses 
guidelines.
Data extraction and management
We will use a standard form to extract data from the 
included studies. This form will consist of the following 
fields, but the list could be longer if necessary:
 ► Study identification.
 ► Study methods including design, inclusion and exclu-
sion criteria.
 ► Study population including baseline characteristics.
 ► Description of the intervention.
 ► Description of comparator.
 ► Information for assessment of the risk of bias (RoB).
 ► Organ/s involved.
 ► End points.
 ► Results.
We will use different prespecified forms for each 
type of study (randomised controlled trial (RCT), non- 
RCT, uncontrolled trial, cohort studies and case- control 
studies) and type of outcome (dichotomous or quantita-
tive) in order to capture all relevant information.
One review author will extract data and another one 
will check all data have been properly extracted. Discrep-
ancies will be identified and resolved through discussion 
(with a third author where necessary). Missing data will 
be requested from study authors.
Assessment of risk of bias in included studies
Due to the variety of designs we will find, we have planned 
to use several tools to assess the RoB. These tools are listed 
in the table 1.
Two review authors will independently assess each 
included study for RoB. We will resolve disagreements 
by discussion and when necessary by consultation with a 
third review author.
Measures of treatment effect
For continuous data, we have planned to compare the 
values in the intervention and control groups at final 
follow- up timepoint. We expect to use mean differences 
(MDs) with 95% CIs as summary statistics. If studies had 
used different measurement instruments or units to 
measure an outcome, we plan to use the standardised 
mean difference (SMD).
For dichotomous data, we will calculate Mantel- 
Haenszel OR from the numbers of events in control and 
intervention groups. In the case of uncontrolled trials, we 
will account the number of events in the only group. We 
also collect 95% CIs or any statistic which allow to calcu-
late the 95% CIs.
If some studies had reported an outcome as a dichoto-
mous measure and others as a continuous measure for the 
same construct, we will convert results from a relative risk 
to an SMD, if an approximately normal distribution could 
be assumed for the underlying continuous measure.
Assessment of heterogeneity
We will explore clinical and statistical sources of hetero-
geneity among the different groups of studies (RCT, 
non- RCTs and uncontrolled trials). We will assess statis-
tical heterogeneity using I² statistics and χ² test. We will 
consider a result to be statistically significant if p<0.1. 
We will consider values of I² >60% to be an indication 
of ‘moderate’ heterogeneity and values above 85% to 
be ’considerable’ heterogeneity. We may not carry out a 
meta- analysis if I² is high and will document the rationale 
for our decision.
Data synthesis
Where we consider studies sufficiently homogenous in 
terms of participants, interventions and outcomes, we plan 
to synthesise results in a meta- analysis using the random- 
effects model within each of the following groups:
 ► RCT;
 ► Non- RCT;
 ► Uncontrolled trials.
We will perform statistical analysis using the Cochrane 
Collaboration’s statistical software, Review Manager.
Table 1 Risk of bias (RoB) tools by study design
Name of the tool Study design
Cochrane RoB tool13 Randomised 
controlled trials
RoB criteria for EPOC Reviews14 




RoB criteria for EPOC Reviews14 
(guide for review authors on 
assessing study quality)
Controlled before and 
after (CBA) studies
RoB criteria for EPOC Reviews14 




Risk of Bias in non- randomised 
Studies of Interventions (ROBINS I)15
Cohorts studies
Risk of Bias in non- randomised 
Studies of Interventions (ROBINS I)15
Case- controls studies
Risk of Bias in non- randomised 
Studies of Interventions (ROBINS I)15
Uncontrolled before 
and after (CBA) 
studies
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Given the nature of the intervention included, we 
assume that clinical heterogeneity is very likely to impact 
on the results of our review, so we will report the random- 
effects model results, regardless of statistical evidence of 
heterogeneity in effect size.
Provided we are including three types of interventions/
comparators, we will analyse all possible combinations 
reported.
Subgroup analysis
Results will be analysed for the following subgroups:
 ► Type of organ: heart, intestine, kidney, liver, lung, 
HSCT.
 ► Age groups: 0–4, 4–8, 8–12, 12–18 years.
Sex is not initially going to be considered, neverthe-
less if results are clearly disaggregated by sex, we could 
consider to do a subgroup analysis.
Overall quality of the body of evidence: summary of findings table
The quality of evidence for outcomes will be assessed 
using the Grading of Recommendations Assessment, 
Development and Evaluation approach. Quality will be 
determined as high, moderate, low or very low.
Patient and public involvement
Patient and public involvement (PPI) representatives 
worked with us to refine the list of outcomes, however, it 
was difficult to involve patients in other areas of the study 
design due to the very technical methods required to do 
design the protocol. PPI representatives will write a plain 
language summary and design a leaflet for dissemination 
of the final clinical practice guideline to their peers and 
distributing to patient groups.
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Annex I: Search strategy in OvidSP Medline and Epub Ahead of Print. 
"Search ((((((((((""Immunosuppression""[Mesh]) OR ""Immunosuppressive Agents""[Mesh])) OR 
((avoid$ OR minim$ OR free$ OR withdraw$ OR spar$ OR discontinue OR taper$ OR conversion$ 
OR convert$)) OR ((((CS A) OR CSA) OR cyclosporin*) OR ""Cyclosporins""[Mesh])) OR 
((((((((vertical) AND sdz rad) OR everolimus) OR ay 22-989) OR rapamune) OR rapamycin) OR 
sirolimus) OR ""Sirolimus""[Mesh])) OR ((((((myfortic) OR cellcept) OR morpholinoethyl ester) 
OR mycophenolate mofetil) OR mmf) OR mycophenolic acid)) OR (((((((((protopic) OR kujimycin) 
OR fr-900506) OR tsukubaenolide) OR FK506) OR FK 506) OR prograf) OR tacrolimus) OR 
""Tacrolimus""[Mesh])) OR ((((((((((((((((((((thymocyte antibody) OR thymocyte antiserum$) OR 
thymocyte antibody) OR okt 3) OR okt3) OR atg) OR antithymocyte) OR thymoglobulin$) OR 
muromonab cd$) OR lymphocyte antiserum$) OR lymphocyte$ antibody) OR lymphocyte$ 
antibody) OR alg) OR antilymphocyte) OR antilymphocyte serum) OR polyclonal antibody) OR 
polyclonal antibody) OR monoclonal antibody) OR monoclonal antibody) OR ""Antibodies, 
Monoclonal""[Mesh])) AND ((infant[MeSH] OR child[MeSH] OR adolescent[MeSH])))) AND 
((""Transplantation""[Mesh] OR ""transplantation""[Subheading]) AND ((infant[MeSH] OR 
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